Last update Aug. 22, 2019
Compatible
We do not have alternatives for Dicainum since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dicainum is also known as Tetracaine. Here it is a list of alternative known names::
Dicainum in other languages or writings:
Main tradenames from several countries containing Dicainum in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | (Derma: 15) | % |
Molecular weight | 264 | daltons |
Protein Binding | 75 | % |
pKa | 8.5 | - |
T½ | 1.25 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Strong-acting topical anesthetic used in local dermatological, ophthalmologic, oropharyngeal and urological anesthesia. Its use in epidural anesthesia is very rare.
Since the last update we have not found any published data on its excretion in breast milk.
Topical anesthetics (dermatological and stomatological preparations) when well applied have very low systemic absorption so that levels in plasma and, therefore, in breastmilk are zero or insignificant. Absorption is possibly greater if applied to inflamed skin.
The low cutaneous absorption, the rapid hydrolysis of tetracaine in the plasma and its rapid elimination (AEMPS 2014, Galderma 2012) contribute to the fact that after the application of cutaneous topical tetracaine the plasma levels are undetectable or very low (AEMPS 2014, Galderma 2012, Ogden 2008, Terndrup 1992, Mazumdar 1991).
Therefore, it can be considered compatible with breastfeeding (Briggs 2017, Galderma 2012, Schaefer 2007 p632).
It should not be applied over large areas or for prolonged periods to minimize systemic absorption.
Do not apply to the breast to prevent the infant from ingesting it; if necessary, apply after a feed and clean thoroughly with water before the next one.